BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 18956425)

  • 1. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia.
    Akolekar R; Zaragoza E; Poon LC; Pepes S; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Nov; 32(6):732-9. PubMed ID: 18956425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation.
    Poon LC; Zaragoza E; Akolekar R; Anagnostopoulos E; Nicolaides KH
    Prenat Diagn; 2008 Dec; 28(12):1110-5. PubMed ID: 19003787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Da Silva AB; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):400-407. PubMed ID: 32441401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia.
    Yu J; Shixia CZ; Wu Y; Duan T
    Ultrasound Obstet Gynecol; 2011 May; 37(5):528-33. PubMed ID: 20737451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal serum placental growth factor, pregnancy-associated plasma protein-a and free β-human chorionic gonadotrophin at 30-33 weeks in the prediction of pre-eclampsia.
    Lai J; Pinas A; Poon LC; Agathokleous M; Nicolaides KH
    Fetal Diagn Ther; 2013; 33(3):164-72. PubMed ID: 23445908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies.
    Zaragoza E; Akolekar R; Poon LC; Pepes S; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Apr; 33(4):382-6. PubMed ID: 19277983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
    Bakalis S; Peeva G; Gonzalez R; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Oct; 46(4):446-51. PubMed ID: 25826154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.
    Bakalis S; Gallo DM; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):208-15. PubMed ID: 25826797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia.
    Vandenberghe G; Mensink I; Twisk JW; Blankenstein MA; Heijboer AC; van Vugt JM
    Prenat Diagn; 2011 Oct; 31(10):955-61. PubMed ID: 21717483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeks' gestation: data from EVENTS trial.
    Benkő Z; Wright A; Rehal A; Cimpoca B; Syngelaki A; Delgado JL; Tsokaki T; De Alvarado M; Vojtassakova D; Malligiannis Ntalianis K; Chaveeva P; Del Campo A; De Ganzo T; Resta C; Atanasova V; Accurti V; Villalain C; Aguilera J; Dojcinovska D; O'Gorman N; Plasencia W; Zingler E; Dutemeyer V; Alvar B; Casanova MC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Feb; 57(2):257-265. PubMed ID: 33142361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
    Tan MY; Syngelaki A; Poon LC; Rolnik DL; O'Gorman N; Delgado JL; Akolekar R; Konstantinidou L; Tsavdaridou M; Galeva S; Ajdacka U; Molina FS; Persico N; Jani JC; Plasencia W; Greco E; Papaioannou G; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Aug; 52(2):186-195. PubMed ID: 29896812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation.
    Francisco C; Wright D; Benkő Z; Syngelaki A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Nov; 50(5):589-595. PubMed ID: 28556556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal serum placental growth factor isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks' gestation in late-onset pre-eclampsia and small for gestational age neonates.
    Nucci M; Poon LC; Demirdjian G; Darbouret B; Nicolaides KH
    Fetal Diagn Ther; 2014; 35(4):249-57. PubMed ID: 24642536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation.
    Sokratous N; Wright A; Syngelaki A; Kakouri E; Laich A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2024 Jan; 63(1):88-97. PubMed ID: 37724582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia.
    Akolekar R; Syngelaki A; Beta J; Kocylowski R; Nicolaides KH
    Prenat Diagn; 2009 Dec; 29(12):1103-8. PubMed ID: 19777530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia.
    Di Lorenzo G; Ceccarello M; Cecotti V; Ronfani L; Monasta L; Vecchi Brumatti L; Montico M; D'Ottavio G
    Placenta; 2012 Jun; 33(6):495-501. PubMed ID: 22459245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
    Foidart JM; Munaut C; Chantraine F; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Jun; 35(6):680-7. PubMed ID: 20205159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.